natgillin/translations-raw huggingface dataset:
The frequency of adverse reactions is defined using the following convention: -very common (more than 1 in 10 animals treated displaying adverse reaction (s) -common (more than 1 but less than 10 animals in 100 animals treated) -uncommon (more than 1 but less than 10 animals in 1,000 animals treated) -rare (more than 1 but less than 10 animals in 10,000 animals treated) -very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10 loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10 loomal 10,000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud üksikjuhud).
Expert, prompt, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Tuleb osutada KOHEST kirurgilist abi, vajalikuks võib osutuda süstepiirkonna lõikus ja loputamine, eriti kui kaasatud on sõrme koed või kõõlus.
Administer 1 dose (0.5 ml) of the veterinary medicinal product to rabbits from the age of 30 days by subcutaneous injection in the lateral thoracic wall.
Manustage küülikutele 1 annus (0,5 ml) veterinaarravimit 30. elupäevast alates nahaaluse süstiga rindkere lateraalsesse seina.
For active immunisation of rabbits from the age of 30 days to reduce mortality caused by the rabbit haemorrhagic disease type 2 virus (RHDV2).
Küülikute aktiivseks immuniseerimiseks alates 30 päeva vanusest, et vähendada küülikute hemorraagia tüüp 2 viiruse (RHDV2) põhjustatud suremust).
Mineral oil: ………………..104.125 mg
Mineraalõli: ………………104,125 mg
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
TOIMEAINE(TE) JA MUUDE AINETE
Duration of immunity: 12 months demonstrated by challenge
Immuunsuse kestus: nakkuskatses demonstreeritud 12 kuud.
To stimulate active immunity against the rabbit haemorrhagic disease type 2 virus (RHDV2).
Küülikute hemorraagilise haiguse viiruse 2. tüübi (RHDV2) vastase aktiivse immuunsuse tekitamiseks.
EXP {month/year} Once broached use immediately.
Kõlblik kuni {kuu/aasta} Pärast avamist otsekohe kasutada.
Thiomersal: ………………..0.05 mg
Tiomersaal: ………………0,05 mg
Thiomersal…………0.05 mg
Tiomersaal………………0,05 mg
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
LISA II A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAVAD TOOTJAD
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 …..≥70% cELISA40* (*) ≥70 % of vaccinated rabbits shall give cELISA antibody titres equal to or higher than 40.
Küülikute hemorraagilise haiguse viiruse 2. tüüp (RHDV2), tüvi V-1037……≥ 70% cELISA40* (*) ≥ 70% vaktsineeritud küülikutest on cELISA antikeha tiitrid 40 või suuremad.
Cardboard box of 1 glass vial of 40 doses (20 ml).
1 klaasviaal 40 annusega (20 ml) pappkarbis.
ERAVAC emulsion for injection for rabbits
ERAVAC süsteemulsioon küülikutele
10 x 1 dose (0.5 ml).
10 klaasviaaliga 1 annuse (0,5 ml) pappkarbis.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE
VÄLISPAKENDIL JA SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PAKEND
Pregnancy:
Arstile:
1 x 10 doses (5 ml).
10 x 1 annuse (0,5 ml) 1 x 10 annusega (5 ml) 1 x 40 annusega (20 ml)
ERAVAC emulsion for injection for rabbits.
ERAVAC süsteemulsioon küülikutele.
Cardboard box of 1 glass vial of 10 doses (5 ml).
1 klaasviaal 10 annusega (5 ml) pappkarbis.
Inactivated RHDV2, strain V-1037: ………….≥70% cELISA40
Inaktiveeritud RHDV2, tüvi V-1037 ≥ 70% cELISA40 ≥ 70% vaktsineeritud küülikutest on cELISA antikeha tiitrid 40 või suuremad.
Name and address of the manufacturer of the biological active substance
Bioloogilis<t>e toimeaine<te> tootja<te> nimi <nimed> ja aadress<id>
The full EPAR for Controloc Control can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Controloc Controli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Controloc Control on 12 June 2009.
Euroopa Komisjon andis Controloc Controli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. juunil 2009.
It was also of the opinion that, based on the experience of the use of pantoprazole, the availability of Controloc Control without medical supervision is appropriate.
Inimravimite komitee oli ka seisukohal, et pantoprasooli kasutamise kogemust arvestades on Controloc Controli kättesaadavus ilma arstliku järelevalveta asjakohane.
The recommended dose of Controloc Control is one tablet once a day until symptoms have stopped.
Controloc Controli soovitatav annus on üks tablett üks kord päevas kuni sümptomite kadumiseni.
Controloc Control pantoprazole
Controloc Control pantoprasool
Other information about Controloc Control
Muu teave Controloc Controli kohta
This is a summary of the European public assessment report (EPAR) for Controloc Control.
See on ravimi Controloc Control Euroopa avaliku hindamisaruande kokkuvõte.
Controloc Control is a medicine that contains the active substance pantoprazole.
Controloc Control on ravim, mis sisaldab toimeainena pantoprasooli.
The most common side effects with Controloc Control (seen in around 1 patient in 100) are diarrhoea and headache.
Controloc Controli kõige sagedamad kõrvaltoimed (esinenud enam kui 1 patsiendil 10-st) on kõhulahtisus ja peavalu.
Controloc Control must not be used in people who are hypersensitive (allergic) to pantoprazole, soya or any of the other ingredients.
Controloc Controli ei tohi kasutada patsiendid, kes on pantoprasooli, soja või selle ravimi mõne muu koostisaine suhtes ülitundlikud (allergilised).
For more information about treatment with Controloc Control, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Controloc Controliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Controloc Control is used for the short-term treatment of the symptoms of acid reflux in adults.
Controloc Controli kasutatakse refluksisümptomite lühiajaliseks raviks täiskasvanutel.
Controloc Control's benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Controloc Controli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Controloc Control.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
The active substance in Controloc Control, pantoprazole, is a proton pump inhibitor.
Controloc Controli toimeaine pantoprasool on prootonpumba inhibiitor.
Controloc Control is similar to a ‘reference medicine' already authorised in the European Union (EU) called Controloc.
Controloc Control on sarnane võrdlusravimiga Controloc, millel juba on Euroopa Liidus müügiluba.
It is used for long-term treatments and is also used to treat a wider range of gastrointestinal diseases (conditions affecting the gut) than Controloc Control.
Seda kasutatakse pikaajaliseks raviks ja võrreldes Controloc Controliga suurema hulga seedetrakti haiguste (soolehaiguste) raviks.
The reference medicine, Controloc, is only available with a prescription.
Võrdlusravimit Controloci saab üksnes retsepti alusel.
Why has Controloc Control been approved?
Miks Controloc Control heaks kiideti?
What is the risk associated with Controloc Control?
Mis riskid Controloc Controliga kaasnevad?
What is Controloc Control?
Mis on Controloc Control?
What benefit has Controloc Control shown during the studies?
Milles seisneb uuringute põhjal Controloc Controli kasulikkus?
How is Controloc Control used?
Kuidas Controloc Controli kasutatakse?
How has Controloc Control been studied?
Kuidas Controloc Controli uuriti?
What is Controloc Control used for?
Milleks Controloc Controli kasutatakse?
The company requested a re-examination of the initial opinion.
Ettevõte taotles algse arvamuse taasläbivaatamist.
This means that cancer cells cannot divide and they eventually die.
Selle tulemusel ei saa vähirakud jaguneda ja lõpuks hävivad.
What consequences does this refusal have for patients in clinical trials?
Kuidas mõjutab keeldumine praegu kliinilistes uuringutes osalevaid patsiente?
Doxorubicin has been available since the 1960s.
Doksorubitsiini on turustatud alates 1960. aastatest.
Therefore, Caelyx was used instead.
Sel põhjusel kasutati Adriamycini asemel Caelyxit.
Refusal of the marketing authorisation for Doxolipad (doxorubicin) EMA/295022/2019
Doxolipadi (doksorubitsiin) müügiloa andmisest keeldumine EMA/295022/2019
What is Doxolipad?
Mis on Doxolipad?
The company that applied for authorisation is TLC Biopharmaceuticals B.V.
Müügiluba taotles ettevõte TLC Biopharmaceuticals B.V.
The recommendation was confirmed after re-examination.
Pärast taasläbivaatamist kinnitas komitee soovituse.
After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 29 May 2019.
Pärast taotluse aluste arutamist vaatas inimravimite komitee oma arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 29. mail
The company informed the CHMP that there are no ongoing clinical trials with Doxolipad in the EU.
Ettevõte teatas inimravimite komiteele, et Euroopa Liidus Doxolipadi kliinilisi uuringuid praegu ei toimu.
It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins.
Ravim häirib rakkude DNAd, takistades DNA kopeerimist ja valkude tootmist.
For more information on hybrid medicines, see the question-and-answer document here.
Lisateave hübriidravimite kohta on teabedokumendis siin.
This means that Doxolipad was intended to be similar to a ‘reference medicine' already authorised in the European Union called Adriamycin.
See tähendab, et Doxolipad pidi olema sarnane võrdlusravimiga Adriamycin, millel juba on Euroopa Liidus müügiluba.
Refusal of the marketing authorisation for Doxolipad (doxorubicin)
Doxolipadi (doksorubitsiin) müügiloa andmisest keeldumine
Doxolipad was expected to be used to treat metastatic breast cancer in patients at risk of heart problems (‘metastatic' means the cancer has spread to other parts of the body), and cancer of the ovary in women whose previous treatment including a platinum-based cancer medicine has stopped working.
Doxolipadi kavatseti kasutada metastaatilise (siiretega) rinnavähi raviks südameprobleemide riskiga patsientidel ja munasarjavähi raviks naistel, kellel eelnev ravi (sh plaatinapõhise vähiravimiga) enam ei toimi.
Because Doxolipad was developed as a hybrid medicine, the company also presented the results of a study carried out to investigate whether it is ‘bioequivalent' to Caelyx.
Et Doxolipad töötati välja hübriidravimina, esitas ettevõte ka nende uuringute tulemused, milles uuriti, kas ravim on bioekvivalentne Caelyxiga.
How does Doxolipad work?
Kuidas Doxolipad toimib?
On 31 January 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Doxolipad, intended for the treatment of breast and ovarian cancer.
31. jaanuaril 2019 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda Doxolipadi müügiloa andmisest.
They also reduce the medicine's effects on non-cancer cells, so it is less likely to cause some side effects.
Liposoomid nõrgendavad ka ravimi toimet muudele rakkudele peale vähirakkude, mis vähendab kõrvalnähtude tekke tõenäosust.
The liposomes reduce the rate at which the active substance is broken down, allowing it to circulate in the blood for longer.
toimeaine lagunemist, võimaldades sellel püsida vereringes kauem.
Doxolipad is a cancer medicine that contains the active substance doxorubicin.
Doxolipad on vähiravim, mis sisaldab toimeainena doksorubitsiini.
Doxolipad was developed as a ‘hybrid medicine'.
Doxolipad töötati välja hübriidravimina.
Although the reference medicine for Doxolipad is Adriamycin, this could not be used in the bioequivalence study because it contains doxorubicin in a different form (not enclosed in pegylated liposomes).
Kuigi Doxolipadi võrdlusravim on Adriamycin, ei saanud seda ravimit bioekvivalentsuse uuringus kasutada, sest Adriamycin sisaldab doksorubitsiini muus vormis kui pegüülitud liposoomidena.
Therefore, the CHMP was of the opinion that there was insufficient evidence to show that Doxolipad was bioequivalent to Caelyx, and it was not possible to establish that the benefits of Doxolipad outweigh its risks.
Seega oli inimravimite komitee arvamusel, et Doxolipadi ja Caelyxi bioekvivalentsuse tõendamine ei ole piisav ja seega ei olnud võimalik tõestada, et Doxolipadi kasulikkus on suurem kui sellega kaasnevad riskid.
The results of the bioequivalence study showed that Doxolipad is comparable to Caelyx in terms of ‘liposome-encapsulated doxorubicin', but failed to show that the amount of ‘free doxorubicin' is the same for the two medicines.
Bioekvivalentsusuuring tõendas, et Doxolipad on liposoomides sisalduva doksorubitsiini osas Caelyxiga võrreldav, kuid ei tõendanud, et kahe ravimi vaba doksorubitsiini kogus on võrreldav.
On that basis, the CHMP recommended that Doxolipad be refused marketing authorisation.
Sel põhjusel soovitas inimravimite komitee Doxolipadi müügiloa andmisest keelduda.
The applicant presented data from the scientific literature, and data from studies conducted in experimental models, including comparisons with another authorised doxorubicin medicine, Caelyx, which contains doxorubicin in pegylated liposomal form.
Müügiloa taotleja esitas teaduskirjanduse ja eksperimentaaluuringute andmed, sealhulgas ravimiga Caelyx (samuti pegüülitud liposomaalset doksorubitsiini sisaldava müügiloaga ravim) korraldatud võrdlusuuringute andmed.
The difference between the products is that in Doxolipad the active substance doxorubicin is enclosed in tiny fatty spheres called liposomes (see below for more details).
Ravimite erinevus on selles, et Doxolipadi toimeaine doksorubitsiin on kapseldatud liposoomidesse (väga väikesed rasvakuulid; üksikasjalikum teave on allpool).
What was Doxolipad expected to be used for?
Milleks kavatseti Doxolipadi kasutada?
It was to be available as a concentrate to be made into a solution for infusion (drip) into a vein.
Seda kavatseti turustada infusioonilahuse (veeni tilgutava lahuse) kontsentraadina.
In Doxolipad, it is enclosed in ‘pegylated liposomes' (tiny fatty spheres that are coated with a chemical called polyethylene glycol).
Doxolipadis sisaldub toimeaine pegüülitud liposoomides (polüetüleenglükooliga ümbritsetud väikestes rasvakuulides).
The active substance in Doxolipad, doxorubicin, is a cytotoxic medicine that belongs to the group ‘anthracyclines'.
Doxolipadi toimeaine doksorubitsiin on antratsükliinide rühma kuuluv tsütotoksiline ravim.
The full EPAR for Oslif Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst ravimi Oslif Breezhaler kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
European Commission granted a marketing authorisation valid throughout the European Union for Oslif Breezhaler on 30 November 2009.
Euroopa Komisjon andis ravimi Oslif Breezhaler müügiloa, mis kehtib kogu Euroopa Liidus, 30. novembril 2009.
It works by attaching to beta-2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax.
See seondub beeta-2-retseptoritega, mida leidub paljude elundite lihasrakkudes ja mis lõõgastavad lihaseid.
Therefore, the Agency decided that Oslif Breezhaler's benefits are greater than its risks and recommended that it be given marketing authorisation.
Seetõttu otsustas ravimiamet, et ravimi Oslif Breezhaler kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Overall, the effects of the 150 and 300 microgram doses of Oslif Breezhaler were similar, but the results showed that the 300 microgram dose may provide better relief in patients with more severe disease.
Ravimi Oslif Breezhaler 150 ja 300 µg annuste toime oli üldiselt sarnane, kuid tulemused tõendasid, et 300 µg annus võib leevendada raskema haigusega patsientide sümptomeid paremini.
This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
See lõdvestab hingamisteede lihased, hoides hingamisteed avatuna, nii et patsiendil on kergem hingata.
Other common side effects include chest pain, cough and muscle cramps.
Muud sagedad kõrvalnähud on valu rinnus, köha ja lihasekrambid.
What measures are being taken to ensure the safe and effective use of Oslif Breezhaler?
Mis meetmed võetakse, et tagada ravimi Oslif Breezhaler ohutu ja efektiivne kasutamine?
Oslif Breezhaler capsules, which contain a powder for inhalation, are only used with a Oslif Breezhaler inhaler and must not be swallowed.
Ravimi Oslif Breezhaler kapsleid, mis sisaldavad inhalatsioonipulbrit, tohib kasutada üksnes ravimi Oslif Breezhaler inhalaatoris ja neid ei tohi alla neelata.
In three main studies involving over 4,000 patients with COPD, Oslif Breezhaler was compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
Kolmes põhiuuringus, milles osales üle 4000 kroonilise obstruktiivse kopsuhaigusega patsiendi, võrreldi Oslif Breezhalerit platseebo (näiv ravim), tiotroopiumi ja formoterooliga (muud kroonilise obstruktiivse kopsuhaiguse raviks kasutatavad inhaleeritavad ravimid).
The Agency also noted that there were no major safety concerns with Oslif Breezhaler, with side effects being manageable and similar to other beta-2 adrenergic receptor agonist medicines.
Ravimiamet märkis samuti, et ravimiga Oslif Breezhaler ei ole täheldatud suuri ohutusprobleeme ning ravimi kõrvalnähud on hallatavad ja sarnanevad teiste beeta-2-adrenergilise retseptori agonistide kõrvalnähtudega.
Oslif Breezhaler is used for maintenance (regular) treatment.
Ravimit Oslif Breezhaler kasutatakse säilitusraviks (tavaliseks raviks).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oslif Breezhaler have been included in the summary of product characteristics and the package leaflet.
Ravimi Oslif Breezhaler ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
On average, the increase in FEV1 in patients who received Oslif Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml.
FEV1 suurenes keskmiselt 150-190 ml võrra ravimit Oslif Breezhaler saanud patsientidel ja vähenes kuni 10 ml võrra või suurenes kuni 20 ml võrra platseebot saanud patsientidel.
The most common side effects with Oslif Breezhaler (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat) and upper respiratory tract infection (infection of the nose and throat).
Ravimi Oslif Breezhaler kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nasofarüngiit (nina- ja kurgupõletik) ja ülemiste hingamisteede infektsioon.
What is Oslif Breezhaler and what is it used for?
Mis on Oslif Breezhaler ja milleks seda kasutatakse?
Oslif Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Oslif Breezhaler on ravim, mida kasutatakse hingamisteede avatuna hoidmiseks kroonilise obstruktiivse kopsuhaigusega täiskasvanutel.
The active substance in Oslif Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist.
Ravimi Oslif Breezhaler toimeaine indakaterool on beeta-2-adrenergilise retseptori agonist.
This is a summary of the European public assessment report (EPAR) for Oslif Breezhaler.
See on ravimi Oslif Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
For more information about treatment with Oslif Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate ravimiga Oslif Breezhaler toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Why is Oslif Breezhaler approved?
Miks Oslif Breezhaler heaks kiideti?
For practical information about using Oslif Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate ravimi Oslif Breezhaler kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
It is not intended to provide practical advice on how to use Oslif Breezhaler.
Hindamisaruandes ei anta ravimi Oslif Breezhaler kasutamise praktilisi nõuandeid.
Other information about Oslif Breezhaler
Muu teave ravimi Oslif Breezhaler kohta
For the full list of all side effects and restrictions with Oslif Breezhaler, see the package leaflet.
Ravimi Oslif Breezhaler kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
Oslif Breezhaler indacaterol
Oslif Breezhaler indakaterool
When Oslif Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them.
Ravimi Oslif Breezhaler inhaleerimisel puutub indakaterool kokku hingamisteedes olevate retseptoritega ja aktiveerib need.
The European Medicines Agency concluded that Oslif Breezhaler was shown to be effective at improving the lung function in COPD.
Euroopa Ravimiamet järeldas, et ravimi Oslif Breezhaler efektiivsus kopsutalitluse parandamisel kroonilise obstruktiivse kopsuhaiguse korral on tõendatud.
How does Oslif Breezhaler work?
Kuidas Oslif Breezhaler toimib?
What are the risks associated with Oslif Breezhaler?
Mis riskid ravimiga Oslif Breezhaler kaasnevad?
How is Oslif Breezhaler used?
Kuidas ravimit Oslif Breezhaler kasutatakse?
Oslif Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
Oslif Breezhaler oli kroonilise obstruktiivse kopsuhaigusega patsientide kopsutalitluse parandamisel platseebost efektiivsem.
What benefits of Oslif Breezhaler have been shown in studies?
Milles seisneb uuringute põhjal ravimi Oslif Breezhaler kasulikkus?
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom21 November 2014
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
The full European Public Assessment Report for Ceprotin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Ceprotini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What is Ceprotin?
Mis on Ceprotin?
‘Acquired' means that the disease is not inherited but develops during the patient's life and may occur for different reasons such as severe infection, liver disease or vitamin K deficiency.
„Omandatud” tähendab seda, et haigus ei ole pärilik, vaid kujuneb patsiendi elu jooksul ja võib tekkida erinevatel põhjustel, nagu raske nakkus, maksahaigus või K-vitamiini vaegus.
Detailed information on the approved use of Ceprotin in the European Union (EU) can be found here.
Üksikasjalik teave Ceprotini heakskiidetud kasutuse kohta Euroopa Liidus on siin.
The withdrawal letter is available here.
Kiri, milles teatatakse taotluse tagasivõtmisest, on siin.